▶Eli Lilly became the first healthcare company to achieve a $1 trillion market capitalization, a milestone driven largely by the success of its GLP-1 drugs for obesity and diabetes.May–Jun 2026
▶The company has launched a direct-to-consumer platform called Lilly Direct, strategically shifting its business model to sell medications directly to patients and bypass traditional intermediaries like PBMs.May 2026
▶A significant portion of Eli Lilly's revenue and market value is derived from its GLP-1 drug franchise, including Mounjaro and Zepbound, with the company capturing a majority of new patient starts in the U.S.May–Jun 2026
▶Eli Lilly is making substantial capital investments in its manufacturing capabilities, including building new multi-billion dollar plants in the United States to meet the high demand for its products.May 2026
▶There is variance in the reported market capitalization, with some sources citing approximately $700 billion while others confirm the achievement of a $1 trillion valuation, likely reflecting different timeframes of reporting.May 2026
▶While Eli Lilly is gaining significant market share from competitor Novo Nordisk in the obesity drug market, the overall narrative still frames them as one of two dominant players in a highly competitive duopoly, not as an undisputed sole leader.
▶The company's pricing strategy is complex; it faces criticism for high list prices but has also taken steps to mitigate costs for consumers by launching an authorized generic insulin and creating direct-to-consumer channels.
▶The primary driver of current value is the GLP-1 franchise, but the company's aggressive M&A strategy in diverse areas like vaccines, infectious diseases, and sleep disorders suggests an internal push to build future growth engines beyond obesity and diabetes.
Sign up free to see the full intelligence report
Get started free